Addition of E138K to R263K in HIV integrase increases resistance to dolutegravir, but fails to restore activity of the HIV integrase enzyme and viral replication capacity

BACKGROUND: The results of several clinical trials suggest that the integrase inhibitor dolutegravir may be less prone than other drugs to the emergence of HIV drug resistance mutations in treatment-naive patients. We have shown that the R263K mutation commonly emerged during tissue culture selectio...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Mesplède, Thibault, Osman, Nathan, Wares, Melissa, Quashie, Peter K., Hassounah, Said, Anstett, Kaitlin, Han, Yingshan, Singhroy, Diane N., Wainberg, Mark A.
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2014
Assuntos:
Original Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4164141/
https://ncbi.nlm.nih.gov/pubmed/24917583
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jac/dku199
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares